@FiercePharma: "Unnerved" by "weakness in the base business," Jefferies downgrades Glaxo to "hold." Next year = better, firm says. More | Follow @FiercePharma
> The FDA gave its blessing to broader use of Roche's ($RHHBY) eye drug Lucentis in patients with diabetic macular edema. Report
> KV Pharmaceutical got a boost in court when a judge ordered Georgia's Medicaid program to cover the pricey treatment for premature birth; partly because of Makena's stumbles, KV is now in bankruptcy. Report
> GlaxoSmithKline ($GSK) was downgraded by Jefferies after the drugmaker said its margins wouldn't increase as planned this year, thanks to pricing pressures. Report
> Patients at risk of diabetes do see that risk increased with the use of cholesterol-lowering statins, but the cardiovascular benefits of those drugs still outweigh that risk, a Lancet study found. Report
> Ranbaxy Laboratories has moved production of its Lipitor copy to a new plant in Mohali, India, from the U.S. Report
> Express Scripts plans to divest or dissolve some businesses, including a diabetes supply business, a joint venture in China and its business in Germany and France. Report
> India's Cipla plans to revamp its business in China to focus on manufacturing biosimilars and active pharmaceutical ingredients. Report
@FierceMedDev: Given Imaging's rough stock slump last week was a major overreaction, at least one analyst is saying--via Bloomberg. More | Follow @FierceMedDev
@MarkHFierce: MIT tech helped U.K. scientists discover a new class of polymers that could coat med devices and help reduce bacteria. Story | Follow @MarkHFierce
@DamianFierce: Medtronic is looking to get a foothold in China with some M&A. More | Follow @DamianFierce
> U.K. researchers wield MIT tech to discover new class of antimicrobial polymers. Item
> FDA clears Stryker's next-gen stroke treatment device. News
Biotech News
@FierceBiotech: FDA taps data-mining tech for drug safety research. More | Follow @FierceBiotech
@JohnCFierce: Elcelyx sheds stealth status, adds venture bucks as it seeks obesity pacts. More | Follow @JohnCFierce
@RyanMFierce: Mount Sinai's Eric Schadt reflects on first year at $100 million genomics center. More | Follow @RyanMFierce
> Both low and OK'd doses of Acorda's Ampyra fall shy of key endpoint. Article
> Elan stokes buyout buzz with plan for $130M R&D spinout. News
> Elcelyx sheds stealth status, adds venture bucks as it seeks obesity pacts. News
Biotech IT News
> BioClinica accelerates spending to support eClinical surge. Article
> Sanofi trains social-media eye on diabetics. Story
> U.K. scientists tap into e-health research with Centers of Excellence. More
CRO News
> Theorem and Gallus team up to offer CRO, CMO services. Article
> Charles River bolsters IT spending to stand out in CRO crowd. Story
> Fuji Pharma jumps into CMO game with $53.4M plant buy. More
And Finally... Daily aspirin may protect against cancer, but perhaps not as much as previously thought. Report